References

1. Anonymous. Sublingual apomorphine: new preparation. In erectile disorders: a narrow therapeutic margin. Prescrire Int 2002; 11(59):76–79. [PubMed: 12068841]
2. De Siati M, Saugo M, Franzolin N. The start of pharmacological activity after sublingual administration of sildenafil citrate in 30 patients affected by erectile dysfunction. Arch Ital Urol Androl. 2003;75(1):18–20. [PubMed: 12741340]
3. Gogtay NJ, Bichile SK, Pinto CJ. et al. Erectile dysfunction and sildenafil citrate.[comment] J Assoc Physicians India. 2001;49:871–872. [PubMed: 11837751]
4. Guay AT, Perez JB, Velasquez E. et al. Clinical experience with intraurethral alprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study. Medicated urethral system for erection. Eur Urol. 2000;38(6):671–676. [PubMed: 11111182]
5. Tsai YS, Lin JS, Lin YM. Safety and efficacy of alprostadil sterile powder (S. Po., CAVERJECT) in diabetic patients with erectile dysfunction. Eur Urol. 2000;38(2):177–183. [PubMed: 10895010]
6. Cecchi M, Sepich CA, Felipetto R. et al. Vacuum constriction device and topical minoxidil for management of impotence. Arch Esp Urol. 1995;48(10):1058–1059. [PubMed: 8588728]
7. Brooks DP, Giuliano F. Genitourinary diseases. Drug Discovery Today: Therapeutic Strategies 2005; 2(1):iii–iiv.
8. Anonymous. Erratum: Efficacy and tolerability of sildenafil in Indian males with erectile dysfunction: A double-blind, randomized, placebo controlled, crossover study (Indian Journal of Pharmacology (2004) vol. 37 (5) (317)). Indian Journal of Pharmacology 2004; 36(6):391.
9. Bayes M, Rabasseda X, Prous JR. Gateways to Clinical Trials. Methods & Findings in Experimental & Clinical Pharmacology 2004; 26(9):723–753. [PubMed: 15632957]
10. Martinez-Jabaloyas JM, Gil-Salom M, Villamon-Fort R. et al. Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol. 2001;40(6):641–647. [PubMed: 11805410]
11. Grover JK, Vats V, Ajeeta. Sildenafil (Viagra(TM)). Medico-Legal Update 1998; 3(1–2):67–78.
12. Canale D, Giorgi PM, Lencioni R. et al. Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction. Int J Androl. 1996;19(1):28–32. [PubMed: 8698535]
13. Chiang HS, Kao YH, Sheu MT. Papaverine and prostaglandin E1 gel applications for impotence. Ann Acad Med Singapore. 1995;24(5):767–769. [PubMed: 8579329]
14. Anonymous. Alprostadil for erectile impotence. Drug Ther Bull 1995; 33(8):61–62. [PubMed: 8529540]
15. Cara AM, Lopes-Martins RAB, Antunes E. et al. The role of histamine in human penile erection. Br J Urol. 1995;75(2):220–224. [PubMed: 7850330]
16. Shabsigh R. Efficacy of sildenafil citrate (VIAGRA) is not affected by aetiology of erectile dysfunction. Int J Clin Pract. 1999;102(Jun.):19–20. [PubMed: 10665116]
17. Padma-Nathan H. Oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction: assessment of erections hard enough for sexual intercourse. Int J Clin Pract. 1999;102(Jun.):13–15. [PubMed: 10665114]
18. McMahon C. Comparison of erectile responses to differing doses of prostaglandin PGE1 in an attempt to standardise pharmacological diagnosis of impotence. Journal of Assisted Reproduction & Genetics. 1992;9:265A.
19. Bartlik BD, Kaplan P, Kaplan HS. Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin re-uptake inhibitors. J Sex Marital Ther. 1995;21(4):264–271. [PubMed: 8789508]
20. El Malik EMA. Erectile dysfunction: An update of diagnosis and management. Qatar Medical Journal. 2000;9(2):9–17.
21. Varela SM, Cadarso SC, Garcia R, V et al. Sildenafil citrate in treatment of 100 patients with erectile dysfunction. Actas Urologicas Espanolas. 2001;25(5):335–340. N. [PubMed: 11512257]
22. Wespes E, Sternon J, Hirsch E. et al. Sildenafil (Viagra(TM)). Revue Medicale de Bruxelles. 1998;19(5):437–441. N. [PubMed: 9844484]

Footnotes

Appendixes and Evidence Tables for this report are provided electronically at http://www​.ahrq.gov/downloads​/pub/evidence​/pdf/erectiledys/erecdys.pdf